Comparative Pharmacology
Head-to-head clinical analysis: PENICILLIN VK versus UNIPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PENICILLIN VK versus UNIPEN.
PENICILLIN-VK vs UNIPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Penicillin VK inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
Unipen (nafcillin) is a penicillinase-resistant penicillin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), blocking transpeptidation and autolysin inhibition.
250-500 mg orally every 6-8 hours for mild to moderate infections; 500 mg orally every 6 hours for severe infections (e.g., streptococcal pharyngitis, skin infections).
500 mg to 2 g orally or intravenously every 4 to 6 hours; maximum 12 g/day IV for serious infections.
None Documented
None Documented
0.5 hours (normal renal function); prolonged to 3-10 hours in severe renal impairment (CrCl <10 mL/min).
0.5-1 hour in normal renal function; prolonged to 7-10 hours in anuria or severe renal impairment.
Renal: 20-40% unchanged via tubular secretion; hepatic metabolism to penicilloic acid; biliary/fecal: minimal (<5%).
Renal: 70-90% unchanged via tubular secretion and glomerular filtration; biliary: minor (<10%); fecal: minimal.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic